Response to Letter to the Editor Re: “EUS-Guided Intragastric Injection of Botulinum Toxin A in the Preoperative Treatment of Super-Obese Patients: a Randomized Clinical Trial”
- 11 Downloads
Thank you for your interest in our randomized controlled trial of EUS-guided intragastric injection of botulinum toxin A (BTX-A) in super obese patients . We agree that injection of botulinum toxin A is a very controversial topic and we are happy to answer your questions.
First, Regarding a BTX-A Injection
On page three of the article in the left column, we briefly described that 40 units of BTX-A were injected in five different regions with a total of 200 BTX-A units injected per patient. Then, in the right column, we describe the injections in further detail. First, 12 microinjections containing 10 units of BTX-A were performed at respective points: four microinjections at 3 cm from the pyloric sphincter (region 1), repeated twice in the direction of gastric cardia (region 2 and 3), at 2 cm intervals, followed by four injections performed around the gastric cardia (region 4), and four injections in the region of the greater curvature (region 5).
IBR, DTHdM, and EGHdM wrote the response letter and approved the final draft of this manuscript.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.de Moura EGH, Ribeiro IB, Frazão MSV, et al. EUS-guided intragastric injection of botulinum toxin A in the preoperative treatment of super-obese patients: a randomized clinical trial. Obes Surg [Internet]. 2018; Available from: http://link.springer.com/10.1007/s11695-018-3470-y. Accessed 07/12/2018
- 3.Moura D, Oliveira J, De Moura EG, et al. Effectiveness of intragastric balloon for obesity: a systematic review and meta-analysis based on randomized control trials. Surg Obes Relat Dis. 2016;12(2):420–9.Google Scholar
- 4.Gui D, Mingrone G, Valenza V, et al. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study. Aliment Pharmacol Ther. 2006;23:675–80.Google Scholar
- 5.Mittermair R, Keller C, Geibel J. Intragastric injection of botulinum toxin A for the treatment of obesity. Obes Surg. 2007;17:732–6. Surg [Internet]. 2006;16:335–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16545166. Accessed 07/12/2018
- 6.Foschi D, Corsi F, Lazzaroni M, et al. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes [Internet]. 2007;31:707–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17006442. Accessed 07/12/2018
- 7.Rhee P-L, Lee JY, Son HJ, et al. Analysis of pacemaker activity in the human stomach. J Physiol [Internet]. 2011;589:6105–18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22005683. Accessed 07/12/2018
- 8.Yun H-Y, Sung R, Kim YC, et al. Regional distribution of interstitial cells of Cajal (ICC) in human stomach. Korean J Physiol Pharmacol [Internet]. 2010;14:317–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21165331. Accessed 07/12/2018
- 9.Albanese A, Bentivoglio AR, Cassetta E, et al. Review article the use of botulinum toxin in the alimentary tract. Aliment Pharmacol Ther. 1995;9:599–604.Google Scholar
- 11.Bustamante F, Brunaldi VO, Bernardo WM, et al. Obesity treatment with botulinum toxin-A is not effective: a systematic review and meta-analysis. Obes Surg. 2017;27:2716–23.Google Scholar